SCHEMBL4023643

SCHEMBL4023643

CCC(C)OP(=O)(O)c1cc(Br)ccc1N

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 1/20 0.34
DPP9 Q86TI2 1/20 0.34
DPP7 Q9UHL4 1/20 0.34
KDM4E B2RXH2 2/20 0.34
GLA P06280 1/20 0.34
FBP1 P09467 3/20 0.33
MAPT P10636 4/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
NPC1 O15118 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
RECQL P46063 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
AAK1 Q2M2I8 1/20 0.32
ALDH1A1 P00352 2/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1629454 0.86 ALOX5 (0.34) KDM4EMAPTMEN1KMT2ARECQL
SCHEMBL1631356 0.84 ALOX15 (0.34) DPP8DPP9DPP7SMN1; SMN2ALDH1A1
SCHEMBL1629974 0.83 ALDH1A1 (0.36) KDM4EMAPTCYP1A2RAB9ASMN1; SMN2
SCHEMBL1631592 0.82 MAPK1 (0.37) KDM4EMEN1KMT2ANPC1CYP1A2
SCHEMBL1631192 0.80 HTT (0.41) DPP7MAPTMEN1KMT2ANPC1
SCHEMBL641442 0.80 ALDH1A1 (0.35) KDM4EMAPTALDH1A1
SCHEMBL11648928 0.76 MEN1 (0.39) KDM4EMEN1KMT2ACYP2C9CYP2C19
SCHEMBL1630150 0.76 DPP8 (0.36) DPP8DPP9DPP7SMN1; SMN2ALDH1A1
SCHEMBL5256681 0.74 ALDH1A1 (0.39) KDM4EMAPTMEN1KMT2ANPC1
SCHEMBL6839387 0.74 ALDH1A1 (0.35) KDM4EMAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537075-B1 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH AS (DK) 2009-07-01 EP disclosed
US-20060160856-A1 Diarylurea derivatives and their use as chloride channel blockers NEUROSEARCH A/S (DK) 2006-07-20 US disclosed
EP-1537075-A2 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2005-06-08 EP disclosed
WO-2004022529-A2 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160856-A1 Diarylurea derivatives and their use as chloride channel blockers KIT, ORAI1, CACNA1C DPP8 2517/4885DPP9 1711/4885DPP7 1964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.